Madam Speaker, I thank my colleague for her speech.
As she mentioned, we know that the Patented Medicine Prices Review Board, which regulates drug prices, ties Canadian prices to those of countries where they are most expensive.
We thought we had won our case in 2017, with the publication of proposed regulations that excluded the United States and Switzerland and met our demands. However, as a result of pressure from the pharmaceutical industry, the government withdrew its regulations before they were scheduled to come into force, that is in January 2019.
This time, if I have understood correctly, her government plans to implement this measure in July 2020.